Dr. Hua Yang, PhD is the Vice President of Nonclinical Development and Clinical Pharmacology and offers over 20 years of experience in drug discovery, nonclinical development and clinical pharmacology. Prior to Disc, she served as the Vice President of DMPK and Clinical Pharmacology at Agios Pharmaceuticals, where she established these functions and was instrumental in the discovery, development, and successful approvals of its flagship programs IDHIFA® (enasidinib) in relapsed or refractory AML and TIBSOVO® (ivosidenib) in AML patients with IDH1 mutations, as well as mitapivat (PKR activator) and vorasidenib (dual IDH1/2 inhibitor). Prior to Agios, Hua held positions in DMPK and drug discovery at Millennium/Takeda Pharmaceuticals and Bristol-Myers Squibb. Hua received her BA in Pharmacology from Fudan University, an MS in Pharmacology from Peking Union Medical School and her Ph.D. in Pharmacokinetics from University of Nebraska Medical Center. She is a co-inventor on over 50 patent applications.
May, 2021 - present